TP53 and neoplasm: Alterations in tumor‐related signaling pathways were more frequent in the PD‐L1 positive group compared to the negative group, including RTK/RAS (62% vs. 47%), p53 (46% vs. 12%), DDR (35% vs. 13%), HMT (22% vs. 9%), SWI/SNF (17% vs. 6%), Cell cycle (12% vs. 4%), and KDM (8% vs. 2%).